Clinical study of patients with heart failure under treatment with ozone therapy
Abstract
The ozone for it’s antioxidant, hemorheologic properties, oxygenation enhancers and blood circulation is an alternative treatment for these patients.
We have performed a study where 45 patients who were diagnosed with a chronic stage of II-III HF due to the functional classification of the New York Heart Association (NYHA) and American Cardiology College / American Heart Association (ACC / AHA), previous echocardiogram with a Fracture of Left Ventricular Ejection (LVEF) less than 45%. We administered a Major Autohemotherapy with a protocol of 15 sessions, maintenance every 15 days and cycles every 6 months at 50?g of concentration, an initial dose of 4,000 ?g / ml up to 12,000?g / ml during the 3 years of treatment.
Patients after the first treatment cycle improve their functional physical capacity and LVEF increased to normal levels (55%). It was proved that Autohemotherapy is an adjuvant, viable and beneficial treatment in chronic HF.
Key words: Heart failure (HF), Major Autohemotherapy, Ozone therapy, Fracture of Left Ventricular Ejection
Keywords
Full Text:
PDFReferences
Krumholz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000;139(1):72-77.
Cowie MR. Annotated references in epidemiology. Eur J Heart Fail. 1999;1:101-107.
Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(4 Supl A):6-13.
McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med. 1971;285:1441-1446.
Damasceno A, Cotter G, Dzudie A, Sliwa K, Mayosi BM. Heart Failure in Sub-Saharan Africa: Time for Action. J Am Coll Cardiol. 2007;50(17):1688-1693. doi: 10.1016/j.jacc.2007.07.030.
Cleland JGF, Gemmel I, Khand A, Boddy A. Is the prognosis of heart failure improving?. Eur J HeartFail. 1999;1(3):229-241.
Travagli V, Zanardi I, Bernini P, Nepi S, Tenori L, Bocci V. Effects of ozone blood treatment on the metabolite profile of human blood. Int J Toxicol. 2010 Mar;29(2):165-174. doi: 10.1177/1091581809360069.
Re L. Mawsouf MN, Menéndez S, León OS, Sánchez GM, Hernández F. Ozone Therapy: Clinical and basic evidences of its therapeutic potential. Arch Med Res. 2008;39:17-26. doi: 10.1016/j.arcmed.2007.07.005.
Hurst JW, Morris DC, Alexander RW. The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List. Clin Cardiol. 1999;22(6):385-390.
Borroto-Rodríguez V, Suárez-Fleitas LR, Bocci V, Luisa B, Lima-Hernández LB, Cámbara-Peña R, et al. Ozonoterapia en la Insuficiencia Cardiaca Crónica [Ozonetherapy in chronic heart failure]. Revista Española de Ozonoterapia. 2016;6(1):9-26.
Merin O, Attias E, Elstein D, Schwalb H, Bitran D, Zimran A, et al. Ozone administration reduces reperfusion injury in an isolated rat heart model. J Card Surg. 2007;22(4):339-342. doi: 10.1111/j.1540-8191.2007.00419.x.
Barackat SAE, Saleh NKM, Thabet SS, Salej HA, Fayez MA. Effect of medical ozone therapy on diabetes-induced cardiac dysfunction. JASMR. 2008;3:167-175.
Refbacks
- There are currently no refbacks.
Journal of Ozone Therapy (JO3T)
The Official Peer Reviewed Journal of the World Federation of Ozone Therapy (WFOT)
ISSN 2444-9865